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Abstract Data on genotypic and phenotypic resistance
testing of HIV-1 in the routine clinical setting are lacking.
In a retrospective single-center study, all patients (n=102)
for whom genotypic resistance typing (GRT) and pheno-
typic resistance typing (PRT) were performed during the
calendar year 2002 were examined. GRT and PRT results
were concordant for 79% of the drugs, being highest for
nevirapine (92%) and lowest for didanosine (57%). Con-
cordance of results for protease inhibitors was lowest for
lopinavir (78%) and highest for indinavir (88%). Discor-
dant results for lamivudine were observed in 16% of
patients; 90% of these results corresponded to high-level
resistance by PRT and susceptibility by GRT. Overall, HIV
loads were lower and CD4+ cell counts higher after ther-
apy following resistance testing, but a significant associ-
ation with the number of active drugs as predicted by GRT
or PRT could not be identified. In a subgroup of 43 patients
with virological failure under antiretroviral therapy and
sufficient follow-up data, HIV loads were significantly
lower after 3 and 6 months. More patients with HIV loads
<400/ml had 2 or more active drugs according to PRT
(21/29 [75%]) than according to GRT (15/29 [52%];
p=0.109). This was also found for HIV loads <50/ml (PRT
16/22 [72%], GRT 10/22 [42%]; p=0.103), although the
differences were not statistically significant. There was no
discernable difference between GRT and PRT in the clinic-
based population, but the numbers of resistance tests per-
formed are not sufficient to draw definitive conclusions.
Introduction
Current guidelines recommend testing for HIV drug resis-
tance in HIV-infected patients requiring salvage regimens, in
newly HIV-infected individuals, and in HIV-infected preg-
nant women [1, 2]. These recommendations are based
largely on studies from research settings, and thus their sig-
nificance for the routine clinical situation is unknown.
Several studies, including GART/CPCRA 046 [3], VIR-
ADAPT [4], HAVANA [5], and ARGENTA [6], have
suggested that antiretroviral therapy (ART) guided by
genotypic resistance testing (GRT) with or without expert
advice may improve virological outcome and, possibly,
immunological reconstitution. In some studies, this was cor-
related with a higher number of active drugs prescribed and
was most consistently demonstrable after 12 or 24 weeks of
therapy. In the NARVAL [7] and the VIRA3001 studies [8],
phenotypic resistance testing (PRT) was not associated with
a significantly higher rate of HIV-1 suppression. A recent
study suggests that GRT followed by database interpretation
(virtual phenotype) correlated with a more pronounced
reduction in HIV load than PRT [9]. Longer-lasting efficacy
has not been investigated or was difficult to demonstrate due
to the increasing impact of confounding factors not related to
resistance testing, such as patient adherence to the treatment
regimen, drug tolerability, and comorbidities. More re-
cently, the CERT study randomized patients to routine
PRT, GRT, or “no testing” and found no significant impact
on the long-term virological outcome, but patient compli-
ance was not assessed [10]. In a subgroup of patients with
more than three prior ART regimens, routine PRT, but not
GRT, was associated with a more favorable response. In the
subgroup of non-nucleoside reverse transcriptase inhibitor
(NNRTI)-experienced patients, both PRT and GRT had a
significant impact compared to “no testing” [10]. To better
understand the role of resistance testing in the routine clinical
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situation, we investigated all patients for whom GRT and
PRT were performed during the calendar year 2002 to
determine the level of concordance of GRT and PRT results
as well as the virological outcome of HIV infection.
Patients and methods
TheHIV-1 outpatient clinic Basel served 543HIV-1-infected
individuals at the time of study. During the calendar year
2002, GRT and PRT were ordered for 102 patients by the
treating physicians as part of the routine management. Of
note, tenofovir had been used in Basel only since late 2002,
while efavirenz and lopinavir/ritonavir had been introduced
into the routine more than a year previously, suggesting no
potentially confounding factor of treatment response. ART
was prescribed to 86 (84%) patients within 6 months after
resistance testing, eight of whom were treatment naive. Of
78 ART-experienced patients, 61 (60%) had complete PRT
and GRT for both reverse transcriptase and protease. Of
these 61 patients, 18 were excluded from further analysis due
to various reasons that included plasma viral load below
1,000 copies/ml (n=2), missing follow-up data (n=6), or a
new regimen that included tenofovir or atazanavir (n=10),
leaving 43 patients for further analysis.
Routine GRT was based on the identification of mu-
tations and polymorphisms by cycle sequencing of the
HIV-1 reverse transcriptase and protease genes and their
interpretation according to the algorithm of the Stanford
University Database (http://hivdb.stanford.edu). For the
purpose of this study, the GRT results were grouped as
follows: “susceptible” and “potential low-level resistance”
as susceptible; “low-level resistance” and “intermediate
resistance” as intermediate; and “high-level resistance” as
resistant [11, 12]. PRT was performed using a commercial
assay (PhenoTect; InPheno, Basel, Switzerland) that de-
termined resistance factor RF50 from the ratio of inhibitory
drug concentrations IC50 of the patient-derived reverse
transcriptase- or protease-recombinant virus relative to the
IC50 of a wild-type reference strain pNL4-3 [13, 14]. The
RF50 was interpreted as sensitive, intermediate, or resistant
relative to drug-specific biological cutoff values.
Concordance of GRT and PRT was scored if the same
result was obtained in both assays. Complete discordance
of GRT and PRTwas defined as a result of “susceptible” in
one assay and a result of “resistant” in the other assay.
Partial discordance was defined as a result of “intermedi-
ate-level resistance” in one test, and a result of “suscep-
tible” or “high-level resistance” in the other test. Active
drugs were defined as principally effective as demonstrated
in GRT and/or PRT. Statistical analysis was performed
using S-Plus 2000 software (Insightful Corporation,
Seattle, WA, USA). Descriptive statistics were comple-
mented with measures of association. In a linear regression
model, we assessed the association of individual factors,
with a change in viral load defined as the difference in viral
load between the baseline measurement and the minimal
value during the follow-up period. A p value of <0.05 was
considered significant.
Results
During the calendar year 2002, resistance testing was
ordered for 102 of 543 (19%) HIV-infected patients in our
center. The patient demographics are summarized in
Table 1. Prior AIDS-defining events had been diagnosed
in 40% of the patients. The indication for the resistance
testing was virological failure in 76 (75%) patients.
Twenty-one (20.5%) patients were off treatment at the
time of the present resistance testing. Prior virological
failure was known for 71 (70%) patients, but 92% had a
history of prior exposure to antiretroviral agents, including
zidovudine in 78%, stavudine in 71%, lamivudine in 91%,
and didanosine in 44%. Prior NNRTI exposure was known
in 55% of patients (efavirenz in 30%, nevirapine in 31%).
Prior exposure to proteinase inhibitors was noted in 81%,
including nelfinavir in 69%, indinavir in 46%, and
lopinavir/ritonavir in 21%. In the remaining patients,
nucleotide reverse transcriptase inhibitors (NRTIs) were
prescribed in 78% (zidovudine in 32%, stavudine in 30%,
lamivudine in 56%, didanosine in 20%), NNRTIs in 43%
Table 1 Characteristics of the patients included in the study
No. of patients (%) 102 (100)
No. of males (%) 74 (72.5)
No. of females (%) 28 (27.5)
Median age in years (range) 41 (21–79)
Median duration of HIV-1
diagnosis in years (range)
10 (1–20)
No. (%) in each CDC stage
A 29 (28.4)
B 32 (31.4)
C 41 (40.2)
Median nadir
CD4+ count (cells/μl)
119 (46.5–205.5/2–849)
Median baseline plasma HIV-1
RNA in log10 copies/ml
(25th–75th percentile/range)a
3.83 (2.93–4.41/1.30–6.12)
Median baseline CD4+
count (cells/μl)a
343 (214–519/11–1,074)
No. of patients with ART
experience (%)
94 (92.2)
NRTI 90 (88.2)
NNRTI 52 (55)
PI 78 (81)
No. of patients with prior virologic
failure on ART (%)
71 (70)
Indication for current resistance
testing [no. (%)]
Virologic failure 76 (74.6)
Pregnancy 3 (2.9)
Prior to initiating therapy 21 (20.5)
Others 5 (4.9)
ART antiretroviral therapy, NRTI nucleoside analogue reverse
transcriptase inhibitor, NNRTI non-nucleoside analogue reverse
transcriptase inhibitor, PI protease inhibitor
aBaseline defined as time point of resistance testing
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(efavirenz in 22%, nevirapine in 21%), and proteinase
inhibitors in 47% (nelfinavir in 21%, indinavir in 2%,
lopinavir in 18%).
According to the results of GRT, the most frequently
identified high-level resistance mutations in the reverse
transcriptase were those causing resistance to lamivudine
(with M184V identified in 39%), followed by those causing
resistance to nevirapine (37%), efavirenz (30%, with K103N
identified in 26%), abacavir (17%), and zidovudine (14%,
with M41L identified in 20% and T215Y/F in 21%).
Multidrug resistance associated with mutations Q151M and
K65R amounted to less than 2%. The most frequent high-
level protease resistance identified by GRT affected the
efficacy of nelfinavir (22%) and indinavir (13%), but rarely
that of lopinavir (2%). A multitude of mutations were
observed, including L90M (16%), D30N (7%), I84V (6%),
and I54V (4%). PRT identified high-level resistance in the
reverse transcriptase, most frequently for lamivudine (52%),
nevirapine (41%), and efavirenz (38%), followed by
abacavir (16%) and zidovudine (14%). High-level resistance
to proteinase inhibitors as detected by PRT mostly affected
the efficacy of nelfinavir (26%), indinavir (15%), saquinavir
(14%), and lopinavir (12%). No resistance was identified by
GRT or PRT in ten ART-naïve patients.
For 93 of the 102 patients, GRT and PRT results were
available for HIV reverse transcriptase or protease. Overall,
complete concordance between GRT and PRTwas observed
in 79% of the patients, partial discordance in 18%, and
complete discordance in 3%, but drug-specific differences
were found (Fig. 1). Concordance of results was highest for
NNRTIs (92%), followed by lamivudine (84%), and was
lowest for didanosine (57%) and zalcitabine (63%) (Fig. 1).
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Fig. 1 Concordance between
results of genotypic and pheno-
typic resistance testing. Concor-
dance (green) of genotypic and
phenotypic resistance testing
was present if the same result
was obtained in both assays.
Complete discordance (red) of
GRT and PRT was defined as a
result of “susceptible” in one
assay, and a result of “high-level
resistance” in the other assay.
Partial discordance (orange)
was defined as a result of “in-
termediate-level resistance” in
one test, and a result of “sus-
ceptible” or “high-level resis-
tance” in the other test (ABC
abacavir, AZT zidovudine, DDC
zacitabine, DDI didanosine,
D4T stavudine, 3TC lamivudine,
EFV efavirenz, NVP nevirapine,
APV amprenavir, IDV indinavir,
LPV lopinavir, NFV nelfinavir,
RTV ritonvair, SQV saquinavir)
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Fig. 2 HIV load before and
after antiretroviral resistance
testing. Months denote the
average time before and after
resistance testing for the corre-
sponding measurement (day
0=baseline date); gray bounds
around the median indicate the
corresponding 95% CI, the hor-
izontal line indicates the lower
bound of the 95%CI of the
median log plasma RNA at
baseline, and dots indicate
outliers
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Partial and complete discordance was most frequently
observed for didanosine (36% and 8%) and zalcitabine
(34% and 8%) (Fig. 1). Partial and complete discordancewas
also remarkable for lamivudine (7% and 9%, respectively).
High-level resistance to lamivudine was detected in all but
one of these discordant cases by PRT, whereas GRT in-
dicated susceptibility. Complete discordance was observed
less frequently for protease inhibitors (Fig. 1). No case of
complete discordance was observed for lopinavir, but partial
concordance was frequent. In 15 of 19 cases, intermediate
resistance to lopinavir was suggested by GRT, while PRT
indicated resistance and susceptibilty in seven and eight
cases, respectively.
To investigate the impact of resistance testing on the
subsequent therapeutic response, HIV viral loads and CD4+
cell counts were studied in 43 patients with virological
failure under ART and sufficient follow-up of 3–24 months.
The change in viral load and CD4+ cell count over time is
shown in Fig. 2 and Fig. 3. The gray bounds around the
median in each boxplot indicate the 95% confidence interval
(CI) of the respective medians. The horizontal lines in Figs. 2
and 3 indicate the lower and upper bounds of the 95%CI for
the median baseline viral load and the CD4+ cell count,
respectively. There was a significant decrease inmedian viral
load after baseline at all periods. Viral plasma RNA could be
reduced by 1.47 (95%CI, 0.47–2.47) log copies/ml on
average. In Fig. 4, the change in CD4+ cell counts and HIV
loads after resistance testing is shown. More patients with
HIV loads <400/ml or <50/ml had two or more active drugs
according to PRT than according to GRT (21/29 [75%] and
15/29 [52%], respectively; p=0.109, or 16/22 [72%] and
10/22 [42%], respectively; p=0.103). However, this differ-
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Fig. 3 CD4+ cell count before
and after antiretroviral resistance
testing. Months denotes the
average days before and after
resistance testing for the corre-
sponding measuremement (day
0=baseline date); gray bounds
around the median indicate the
corresponding 95%CI, the hor-
izontal line indicates the upper
bound of the 95%CI of the
median CD4+ cell count at
baseline, and dots indicate
outliers
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Fig. 4 Change in HIV load and
CD4+ cell counts after resis-
tance testing
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ence was not statistically significant. The results of the
univariate regression showed that the number of new active
antiretroviral drugs according to PRTor GRTwas associated
with a reduction in viral load, but the results reached
statistical significance only for PRT. This analysis showed
that, for example, new active drugs as measured by PRT
accounted for close to 28% of the reduction in viral load
(Table 2). The CD4+ cell count increased by an average of
146 cells/mm3 (95%CI, 104–188), which was more obvious
in the first 3–6 months after resistance testing but did not
reach statistical significance. No association between any
predictor and an increase in CD4+ cell count could be found.
Discussion
In this retrospective single-center study, the prevalence of
HIV drug resistance and the concordance of GRT and PRT
results were investigated in 102 patients for whom GRT
and PRT were performed as part of routine clinical care
during the calendar year 2002. The main indication for
resistance testing was ART failure (75% of the tests
prescribed). The demographics of these patients indicate a
long-standing history of HIV infection and considerable
ART experience with prior treatment failures, hence re-
presenting complex salvage situations that pose a major
challenge for HIV care with regard to morbidity, mortality,
and toxicity. Our data indicate a high rate of overall
concordance of 79% between the results of GRT and PRT,
whereas rates of partial and complete discordance were
18% and 3%, respectively. Although the number of patients
in this study is small, more than 1,200 pairs of GRT/PRT
results for the individual drugs were analyzed; thus, more
than 200 partially discrepant results and more than 30
completely discrepant results were obtained.
Discrepant results were observed more frequently for
NRTIs, particularly didanosine and zalcitabine. This is not
unexpected, given the complex multistep development of
resistance to these drugs and the ensuing methodological
limitations of identifying biological, clinical, and penalty
thresholds that are used to report susceptible, intermediate,
and resistant viral mutants. It is interesting to note that
complete discordance for didanosine and zalcitabine re-
sulted mostly from GRT results indicating resistance, but
PRT results indicating susceptibility (11 of 12 cases;
Fig. 1). Similar methodological and biological limitations
may apply to the detection and reporting of resistance to
protease inhibitors, but mostly partial discordance was
noted. For lopinavir, resistance may be particularly difficult
to predict by GRT given the stepwise accumulation of more
than six mutations. In the present study, partial discordance
of results for lopinavir involved intermediate resistance
detected by GRT in 15 of 18 cases, half of which were
scored as resistant by PRT, while the other half was scored
as susceptible by PRT. In contrast, concordance was highest
for NNRTI resistance, as this was caused mostly by the
point mutation K103N in GRT, which correlated well with
high-level resistance in PRT. By the same token, the high
number of discordant results for lamivudine is remarkable,
since detection of M184V clearly indicates high-level re-
sistance. Of note, complete discordance for lamivudine was
due to GRT results being scored as susceptible in seven of
eight cases with documented exposure, while PRT results
were scored as resistant. Given the known impairment of
the viral replication rate by the M184V mutation, a possible
explanation for this discordance could be that the higher
sensitivity of PRT allowed detection of minority popula-
tions of <30% in mixtures of virus populations that are
known to escape routine detection by GRT.
As concordance of both assays was fairly high, the
question arises whether partial and complete discordance
might impact HIV surrogate markers in a clinical setting.
As a first step, we examined the course of the HIV load and
the CD4+ cell count in 43 ART-experienced patients for
whom sufficient follow-up data were available. The data in
Figs. 2 and 3 suggest that the treatment administered after
the resistance testing did show some benefit with regard to
the overall HIV load and CD4+ cell count. In this subgroup
of 43 patients, suppression of HIV loads of up to <400 and
<50 copies per milliliter were observed more often in
patients treated with two or more active drugs as defined by
PRT than by GRT, but this difference did not reach
statistical significance (p=0.109). A more detailed analysis
suggested that a reduction in viral load was significantly
greater among patients who were switched to a regimen of
active drugs as defined by PRT (p=0.013), which was not
observed to the same extent for new active drugs as defined
by GRT (p=0.052). Overall, the differences between GRT
and PRT are marginal and illustrate the limitations of
resistance studies in the clinical setting. Furthermore, the
decrease in HIV load did not translate into a statistically
significant increase in the CD4+ cell counts within the
observation period. A limitation of this study is that re-
sistance testing was investigated in diverse clinical settings
as seen in routine outpatient care. On the other hand, this
allowed us to assess concordance between the two resis-
tance tests in the entire population.
Although the small number of patients and the retro-
spective character of this study clearly limit the conclusions,
we believe that the role of GRT and PRT in the clinical
routine situation warrants further study. The recently pub-
lished CERT study reported a significant benefit in the long-
Table 2 Univariate analysis of factors associated with a change in
viral load
Variable p value R2a
Time to minimal HIV load after testing 0.306 0.025
New active drugs by GRT 0.052 0.178
New active drugs by PRT 0.013 0.278
Active drugs by GRT 0.356 0.134
Active drugs by PRT 0.125 0.201
Age 0.974 0.000
Gender 0.555 0.008
CD4+ cell count at baseline 0.844 0.000
aIndicates the percentage of variability of the response variable
(change in log viral load) explained by the respective predictor
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term efficacy of PRT over GRT or “no testing” in patients
with a history of more than three ART regimens [10]. Like
the high rates of concordance between GRT and PRT for
NNRTIs observed in our study, these authors observed that
both GRT and PRT were more likely to provide a durable
response to therapy than “no testing” in NNRTI-experienced
patients [10]. Despite the potential role of resistance testing
for choosing efficacious salvage regimens, it is clear that the
careful examination and interpretation of the individual
treatment history is still required, since neither GRT nor PRT
efficiently detects latent resistant strains archived during
previous treatment failures.
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